Arca
Skip to content
Tools
Tools

Osteogenesis imperfecta

Drug research and approvals for osteogenesis imperfecta: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 11 studies of osteogenesis imperfecta are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 12 open orphan designations naming it.

  • Recruiting worldwide: 11
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 11 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 8

Phase 2 1

Phase 1 or earlier 5

How its trials ended

76 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 14 whose ending is known, 36% met their primary endpoint, 7% missed it and 57% stopped early.

  • Completed, result not reported3343%
  • Ongoing2533%
  • Met its primary endpoint57%
  • Status unknown45%
  • Stopped: sponsor or business decision34%
  • Stopped: safety23%
  • Stopped: other or unclear23%
  • Missed its primary endpoint11%
  • Stopped: enrollment or feasibility11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 23, 2025A phase 2, multi-center, randomized, double-blind, placebo-controlled, doseranging study to evaluate the safety and efficacy of AGA2115 in adults with type i,…AGA2115Angitia Incorporated LimitedOngoing
Jun 30, 2023A phase 3, open-label, multicenter, randomized study to evaluate the efficacy and safety of romosozumab compared with bisphosphonates in children and…Evenity (romosozumab)AmgenOngoing
May 24, 2023An open-label, randomized, active-controlled, phase 3 study of setrusumab compared with bisphosphonates in pediatric subjects with osteogenesis imperfecta…SetrusumabUltragenyx PharmaceuticalClosed
Mar 4, 2022A phase 1b, single ascending dose, randomized, double-blind study to evaluate the safety, tolerability, and activity of SAR439459 in adults with osteogenesis…SAR439459Sanofi-Aventis Canada IncOngoing
Feb 7, 2022A randomized, double-blind, placebo-controlled, phase 2/3 study to assess the efficacy and safety of setrusumab in subjects with osteogenesis imperfecta (OI)Setrusumab (BPS804)Ultragenyx PharmaceuticalOngoing
Oct 3, 2018"multicenter, single-arm open-label extension study to assess long-term safety and efficacy of current or prior treatment with denosumab in children/young…Prolia®AmgenOngoing
Apr 13, 2017A phase 2b, multicentre, multinational, placebo-controlled, double-blind, dose-finding study in adult patients with type i, iii or iv osteogenesis imperfecta…BPS804 (setrusumab)Mereo Biopharma 3 LimitedOngoing
Jul 16, 2014Prospective, multicenter, single-arm study to evaluate efficacy, safety and pharmacokinetics of denosumab in children with osteogenis imperfecta protocolDenosumabAmgenClosed

FDA orphan designations

Approved first, then open designations, newest first
Sep 21, 20264-(2-Methylanilidocarbamoyl)-phenylacetyl-L-Citrullyl-L-Glut…Treatment of osteogenesis imperfectaZhongshan LaiBo RuiChen BioMedicine Co., Ltd.(RabPharma)Designated
Nov 25, 2025N-[(2S)-1-[(3aS,6R,6aR)-6-Ethynyl-3-oxohexahydro-2H-furo[3,2…Treatment of osteogenesis imperfectaOsteoCat Therapeutics ABDesignated
May 29, 2024Anti-Siglec-15 monoclonal antibody on a human…Treatment of osteogenesis imperfectaNextCure, Inc.Designated
Nov 3, 2022DNA,…Treatment of Osteogenesis ImperfectaAptacure Therapeutics LimitedDesignated
Oct 20, 2022A Humanized Bispecific Antibody Neutralizing Both…Treatment of Osteogenesis imperfecta (OI)Angitia Biopharmaceuticals Guangzhou LimitedDesignated
Oct 15, 2022Anti-human transforming growth factor beta (TGF-Beta)…Treatment of Osteogenesis ImperfectaSanofi Genzyme, A Sanofi CompanyDesignated
May 6, 2022Allogenic fetal mesenchymal stem cellsTreatment of Osteogenesis ImperfectaBOOST Pharma ApsDesignated
May 10, 2021RomosozumabTreatment of Osteogenesis ImperfectaAmgen Inc.Designated
Aug 19, 2019DNA,…Treatment of Osteogenesis ImperfectaAptacure Therapeutics LimitedDesignated
Feb 29, 2016Human monoclonal antibody targeting human sclerostinTreatment of osteogenesis imperfecta.Ultragenyx Pharmaceutical, Inc.Designated
Nov 9, 2015Human allogeneic bone marrow derived osteoblastic cellsTreatment of osteogenesis imperfecta.Biosenic SADesignated
Mar 31, 2003AlendronateTreatment of osteogenesis imperfecta in pediatric patients 4 years of age and olderMerck, Sharpe & Dohme Corp.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.